ArticleHaematologica2017

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.

Amir T Fathi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.